# HERO (NCT07207824)

> DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC

No report yet. It can be ordered.

- Drugs tested: disitamab vedotin
- Indication: HER2-expressing BCG-naïve high-risk non-muscle-invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07207824
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Fudan University
- Conditions: Bladder (Urothelial, Transitional Cell) Cancer; NMIBC
- Interventions: Active Comparator: BCG induction and maintenance; DV + BCG induction and maintenance
- Enrollment: 182
- Primary outcome: Event free survival

## Indexed commentary on HERO so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 56
- Podcasts: 34
- YouTube: 26

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=hero-nct07207824

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07207824", "email": "<work email>"}; the inbox owner confirms by the emailed link.